Please assess the completion status of the following clinical trial:

Trial Title: Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed the preceding trial SP709 (NCT00243217)~Exclusion Criteria:~* Subject did suffer from a serious adverse event during trial SP709 (NCT00243217) which is ongoing at the end of that trial and is assessed to be related to the study medication by the investigator and/or the Sponsor~* Sleep disturbances~* Further clinically relevant concomitant diseases such as polyneuropathy, akathisia, claudication, varicosis, muscle fasciculation, painful legs and moving toes, or radiculopathy~* Other central nervous diseases~* One psychotic episode since start of study SP709~* Any medical or psychiatric condition, which in the opinion of the investigator can jeopardize or would compromise the subject's ability to participate in this trial~* Clinically relevant cardiac dysfunction and arrhythmias~* The subject has at entry in study SP710, a QTc interval ≥ 500 msec and/or a QTc interval which has increased by ≥ 60 msec as compared to the average baseline (Visit 2) QTc interval of study SP709~* Subject has clinically relevant renal dysfunction (serum creatine ≥ 2.0 mg/dl)~* Subject has clinically relevant hepatic dysfunction (total bilirubin \> 2.0 mg/dl or ALT and/or AST greater than two times the upper limit of the reference range~* Subject has a newly diagnosed or relapsing neoplastic disease since the start of study SP709~* Subject has a known hypersensitivity to any components of the trial medication or comparative drugs as stated in this protocol~* Subject needs drugs prohibited in the course of this trial: neuroleptics, bupidine, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive therapy, psychostimulatory drugs, other L-Dopa or dopamine agonist therapy, opioids, benzodiazepines, MAO inhibitors, sedative antihistamines, amphetamines~* Subject is abusing alcohol or drug since start of SP709~* Subject is pregnant or nursing or woman of child-bearing potential who is not surgically sterile, two years postmenopausal, or does not practice two combined methods of contraception, unless sexually abstinent~* Subject pursues shift work or is subject to other continuous non-disease-related life conditions which do not allow regular sleep at night~* Subject has clinically relevant vasculopathies (eg, varix or arteriosclerosis)~* Subject has significant skin hypersensitivity to adhesive or other transdermals or recent unresolved contact dermatitis~* Subject has symptomatic orthostatic hypotension, or a systolic blood pressure (SBP) less tham 105mmHg and/or a drop in SBP of \> 20mmHg or a drop of \> 10mmHg in diastolic BP (DBP) on standing at baseline visit (Visit 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine trans-dermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).